4 DOSES
PER YEAR

Convenient dosing schedule every 12 weeks after 2 starter doses at Weeks 0 and 4.

LEARN MORE

RESOURCES

Support to help your patients start and stay on STELARA®

ACCESS NOW

STELARA®:

A LEGACY IN THE TREATMENT OF PLAQUE PSORIASIS

STELARA®

has been clinically studied for 19 years 1 *

More than 8000 dermatologists have prescribed STELARA® in the

United States1 † ‡

More than 300,000 adult patients with moderate to severe plaque psoriasis treated with STELARA® in the

United States1 §

STELARA® has an estimated cumulative exposure of

1,600,000 patient-years

worldwide since launch1 ║

*A phase 1 clinical trial of STELARA® was initiated in 2001 in patients with moderate to severe plaque psoriasis. Phase 3, double-blind, placebo-controlled, multicenter trials PHOENIX 1 and PHOENIX 2 began in 2005 and 2006, respectively.

†IQVIA-Xponent data. Dermatologists who have written at least 1 prescription for STELARA® in the United States from July 2017 to August 2019.

‡Reflects usage across all lines of therapy.

§More than 300,000 adult patients treated with STELARA ® in the United States from September 2009 to December 2019. Estimations are based on calculations using product-utilization data collected in the United States for STELARA ® to determine patient type, average dose per administration, total number of administrations, and patient persistency rates.

║Based on worldwide estimated number of patient-years from launch through December 2019. Patient-years were estimated by calculations using STELARA ® distribution data to determine average yearly dose while considering regional estimates of patient compliance to dosing regimen.


Reference: 1. Data on file. Janssen Biotech, Inc.

cp-168045v5 02/26